Group One Trading
ADAP

Group One Trading’s Adaptimmune Therapeutics ADAP Stock Holding History

Group One Trading’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-35,700
Closed -$56.4K – 6620
2024
Q1 		$56.4K Buy
+35,700
New +$43.1K ﹤0.01% 4617
2023
Q3 		– Sell
-50,000
Closed -$46.3K – 7563
2023
Q2 		$46.3K Buy
+50,000
New +$59.6K ﹤0.01% 5339
2022
Q4 		– Sell
-2,000
Closed -$2K – 7141
2022
Q3 		$2K Hold
2,000
– – ﹤0.01% 7100
2022
Q2 		$3K Sell
2,000
-6,700
-77% -$11.5K ﹤0.01% 7261
2022
Q1 		$18K Sell
8,700
-22,800
-72% -$61.5K ﹤0.01% 6803
2021
Q4 		$118K Sell
31,500
-31,400
-50% -$143K ﹤0.01% 5574
2021
Q3 		$325K Buy
62,900
+47,600
+311% +$214K ﹤0.01% 4658
2021
Q2 		$65K Buy
15,300
+9,600
+168% +$46.6K ﹤0.01% 6345
2021
Q1 		$30K Buy
+5,700
New +$32.6K ﹤0.01% 6546
2020
Q4 		– Sell
-3,300
Closed -$26K – 6404
2020
Q3 		$26K Sell
3,300
-81,000
-96% -$709K ﹤0.01% 5003
2020
Q2 		$844K Buy
84,300
+80,400
+2,062% +$505K ﹤0.01% 2188
2020
Q1 		$11K Buy
+3,900
New +$12.9K ﹤0.01% 4512
2019
Q2 		– Sell
-7,700
Closed -$33K – 4886
2019
Q1 		$33K Sell
7,700
-15,100
-66% -$70.3K ﹤0.01% 3784
2018
Q4 		$131K Buy
22,800
+5,900
+35% +$43.5K ﹤0.01% 2993
2018
Q3 		$229K Buy
16,900
+14,900
+745% +$156K ﹤0.01% 2918
2018
Q2 		$24K Buy
+2,000
New +$24.9K ﹤0.01% 4298

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Group One Trading's ADAP Position: Q4 2025 in Review

Group One Trading sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 61,730 shares — an estimated $8.03K sold.

Group One Trading first reported a position in ADAP in Q3 2016 and held it in 27 quarters. The position peaked at $287K in Q2 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Group One Trading reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 61,730 Adaptimmune Therapeutics shares in Q4 2025, an estimated $8.03K.
  • Group One Trading first reported a position in Adaptimmune Therapeutics in Q3 2016 and held it in 27 quarters.
  • Group One Trading's Adaptimmune Therapeutics position peaked at $287K in Q2 2020.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.